KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Common Equity (2017 - 2026)

Aquestive Therapeutics has reported Common Equity over the past 9 years, most recently at -$33.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 44.04% year-over-year to -$33.7 million; the TTM value through Dec 2025 reached -$33.7 million, up 44.04%, while the annual FY2025 figure was -$33.7 million, 44.04% up from the prior year.
  • Common Equity for Q4 2025 was -$33.7 million at Aquestive Therapeutics, down from -$4.1 million in the prior quarter.
  • Over five years, Common Equity peaked at -$4.1 million in Q3 2025 and troughed at -$118.6 million in Q4 2022.
  • A 5-year average of -$71.9 million and a median of -$66.8 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 151.4% in 2021 and later soared 90.95% in 2025.
  • Year by year, Common Equity stood at -$82.1 million in 2021, then plummeted by 44.34% to -$118.6 million in 2022, then increased by 10.18% to -$106.5 million in 2023, then surged by 43.51% to -$60.2 million in 2024, then skyrocketed by 44.04% to -$33.7 million in 2025.
  • Business Quant data shows Common Equity for AQST at -$33.7 million in Q4 2025, -$4.1 million in Q3 2025, and -$72.6 million in Q2 2025.